The prevention trials reproduced these results with tamoxifen, reducing the incidence of ER + breast cancer 35%–55% in various trials, while the aromatase inhibitors decreased ER + tumors by almost two-thirds. This evidence concerns the gene CYP19A1 and breast carcinoma.